Show simple item record

dc.contributor.authorKhamis, Mona
dc.contributor.authorAdamko, Darryl
dc.contributor.authorEl-Aneed, Anas
dc.identifier.citationMona M. Khamis, Darryl J. Adamko and Anas El-Aneed. (2017), Development of a validated LC- MS/MS method for the quantification of 19 endogenous asthma/COPD potential urinary biomarkers. Analytica Chimica Acta, 989: 45-58.en_US
dc.description.abstractObstructive airways inflammatory diseases sometimes show overlapping symptoms that hinder their early and correct diagnosis. Current clinical tests are tedious and are of inadequate specificity in special population such as the elderly and children. Therefore, we are developing tandem mass spectrometric (MS/MS) methods for targeted analysis of urine biomarkers. Recently, proton-nuclear magnetic resonance (1H-NMR) analysis proposed 50 urinary metabolites as potential diagnostic biomarkers among asthma and chronic obstructive pulmonary disease (COPD) patients. Metabolites are divided into 3 groups based on chemical nature. For group 1 (amines and phenols, 19 urinary metabolites), we developed and validated a high performance liquid chromatographic (HPLC)-MS/MS method using differential isotope labeling with dansyl chloride. Method development included the optimization of the derivatization reaction, the MS/MS conditions, and the chromatographic separation. Linearity varied from 2 to 4800 ng/mL and the use of 13C2-labeled derivatives allowed for the correction of matrix effects as well as the unambiguous confirmation of the identity of each metabolite in the presence of interfering isomers in urine. Despite the challenges associated with method validation, the method was fully validated as per the food and drug administration (FDA) and the European medicines agency (EMA) recommendations. Validation criteria included linearity, precision, accuracy, dilution integrity, selectivity, carryover, and stability. Challenges in selectivity experiments included the isotopic contributions of the analyte towards its internal standard (IS), that was addressed via the optimization of the IS concentration. In addition, incurred sample analysis was performed to ensure that results from patient samples are accurate and reliable. The method was robust and reproducible and is currently being applied in a cohort of asthma and COPD patient urine samples for biomarker discovery purposes.en_US
dc.description.sponsorshipSaskatchewan Health Research Foundation; AllerGen NCE Inc; Canada Foundation for Innovation; College of Pharmacy and Nutrition, University of Saskatchewanen_US
dc.rightsAttribution-NonCommercial-ShareAlike 2.5 Canada*
dc.titleDevelopment of a validated LC- MS/MS method for the quantification of 19 endogenous asthma/COPD potential urinary biomarkersen_US
dc.description.versionPeer Revieweden_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 2.5 Canada
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 2.5 Canada